Cargando…

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses

Lenalidomide has particular activity in patients with transfusion-dependent del(5q) myelodysplastic syndromes (MDS), but mechanistic information is limited regarding the relationship between erythroid and cytogenetic responses. We reviewed medical records from three distinct subgroups of del(5q) MDS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Giagounidis, Aristoteles A. N., Haase, Sabine, Heinsch, Michael, Göhring, Gudrun, Schlegelberger, Brigitte, Aul, Carlo
Formato:	Texto
Lenguaje:	English
Publicado:	Springer-Verlag 2006
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1705486/ https://www.ncbi.nlm.nih.gov/pubmed/17111142 http://dx.doi.org/10.1007/s00277-006-0217-y

Ejemplares similares

Lenalidomide: a brief review of its therapeutic potential in myelodysplastic syndromes
por: Giagounidis, Aristoteles A N, et al.
Publicado: (2007)

The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
por: Sekeres, Mikkael A., et al.
Publicado: (2018)

Outcomes in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study
por: Giagounidis, Aristoteles, et al.
Publicado: (2014)

Routes of Clonal Evolution into Complex Karyotypes in Myelodysplastic Syndrome Patients with 5q Deletion
por: Feurstein, Simone, et al.
Publicado: (2018)

Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q)
por: Fenaux, Pierre, et al.
Publicado: (2017)

Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2014)

Real-world Data From the Swiss Lenalidomide in MDS del(5q) (SLIM)—Registry Identify New Chances and Challenges in Lenalidomide Treatment of Patients With MDS del(5q)
por: Rüfer, Axel, et al.
Publicado: (2022)

Erratum: Extended survival and reduced risk of AML progression in erythroid-responsive lenalidomide-treated patients with lower-risk del(5q) MDS
por: List, A F, et al.
Publicado: (2015)

Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS
por: Krönke, Jan, et al.
Publicado: (2015)

A European survey on the detection and management of iron overload in transfusion-dependent patients with MDS
por: Giagounidis, Aristoteles, et al.
Publicado: (2011)

Lenalidomide as a disease-modifying agent in patients with del(5q) myelodysplastic syndromes: linking mechanism of action to clinical outcomes
por: Giagounidis, Aristoteles, et al.
Publicado: (2013)

Lenalidomide does not increase AML progression risk in RBC transfusion-dependent patients with Low- or Intermediate-1-risk MDS with del(5q): a comparative analysis
por: Kuendgen, A, et al.
Publicado: (2013)

Haploinsufficiency of ETV6 and CDKN1B in patients with acute myeloid leukemia and complex karyotype
por: Feurstein, Simone, et al.
Publicado: (2014)

Health-Related Quality of Life in Multiple Myeloma Patients Treated with High- or Low-Dose Lenalidomide Maintenance Therapy after Autologous Stem Cell Transplantation—Results from the LenaMain Trial (NCT00891384)
por: Boquoi, Amelie, et al.
Publicado: (2023)

“Randomized phase II study of azacitidine ± lenalidomide in higher-risk myelodysplastic syndromes and acute myeloid leukemia with a karyotype including Del(5q)”
por: Rasmussen, Bengt, et al.
Publicado: (2022)

Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
por: Santini, Valeria, et al.
Publicado: (2020)

Practical recommendations on the use of lenalidomide in the management of myelodysplastic syndromes
por: Giagounidis, Aristoteles, et al.
Publicado: (2008)

Lenalidomide induced durable remission in a patient with MDS/MPN-with ring sideroblasts and thrombocytosis with associated 5q- syndrome
por: Alshaban, Ahmed, et al.
Publicado: (2018)

Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions
por: Valent, Peter, et al.
Publicado: (2017)

Genome-wide DNA methylation analysis pre- and post-lenalidomide treatment in patients with myelodysplastic syndrome with isolated deletion (5q)
por: Hecht, Anna, et al.
Publicado: (2021)

A case of myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) successfully treated with lenalidomide
por: Islam, Anwarul
Publicado: (2015)

CRISPR-Cas9-induced t(11;19)/MLL-ENL translocations initiate leukemia in human hematopoietic progenitor cells in vivo
por: Reimer, Jana, et al.
Publicado: (2017)

Diagnosis of del(5q) MDS, 14 Years after JAK-2 Positive PV Appearance: Complete Remission of both Diseases with Lenalidomide Monotherapy
por: Vaccarino, Antonella, et al.
Publicado: (2016)

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study
por: Platzbecker, U, et al.
Publicado: (2013)

Knockout of the HMG domain of the porcine SRY gene causes sex reversal in gene-edited pigs
por: Kurtz, Stefanie, et al.
Publicado: (2021)

Concomitant Non-Small Cell Lung Cancer and Hairy Cell Leukemia in a Patient Harboring BRAF-V600E Mutation in Both Tissues: A Case Report
por: Mitsogianni, Maria, et al.
Publicado: (2018)

Long-Term Efficacy and Safety of Luspatercept for Anemia Treatment in Patients With Lower-Risk Myelodysplastic Syndromes: The Phase II PACE-MDS Study
por: Platzbecker, Uwe, et al.
Publicado: (2022)

Phase 1 dose-ranging study of ezatiostat hydrochloride in combination with lenalidomide in patients with non-deletion (5q) low to intermediate-1 risk myelodysplastic syndrome (MDS)
por: Raza, Azra, et al.
Publicado: (2012)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Response of high-risk MDS to azacitidine and lenalidomide is impacted by baseline and acquired mutations in a cluster of three inositide-specific genes
por: Follo, Matilde Y., et al.
Publicado: (2019)

SNP Array Karyotyping Allows for the Detection of Uniparental Disomy and Cryptic Chromosomal Abnormalities in MDS/MPD-U and MPD
por: Gondek, Lukasz P., et al.
Publicado: (2007)

Multiplex ligation-dependent probe amplification identifies copy number changes in normal and undetectable karyotype MDS patients
por: Ma, Jing, et al.
Publicado: (2021)

Identification of a Complex Karyotype Signature with Clinical Implications in AML and MDS-EB Using Gene Expression Profiling
por: Lee, Cheonghwa, et al.
Publicado: (2023)

Design and rationale of the QUAZAR Lower-Risk MDS (AZA-MDS-003) trial: a randomized phase 3 study of CC-486 (oral azacitidine) plus best supportive care vs placebo plus best supportive care in patients with IPSS lower-risk myelodysplastic syndromes and poor prognosis due to red blood cell transfusion–dependent anemia and thrombocytopenia
por: Garcia-Manero, Guillermo, et al.
Publicado: (2016)

Effect of TP53 contact and conformational mutations on cell survival and erythropoiesis of human hematopoietic stem cells in a long term culture model
por: Salari, Azam, et al.
Publicado: (2018)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

PP2A: The Achilles Heal in MDS with 5q Deletion
por: Sallman, David A., et al.
Publicado: (2014)

A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS
por: Fenaux, Pierre, et al.
Publicado: (2018)

Proliferative activity is disturbed in myeloproliferative neoplasms (MPN), myelodysplastic syndrome (MDS), and MDS/MPN diseases. Differences between MDS and MDS/MPN
por: Mestrum, Stefan G. C., et al.
Publicado: (2020)

Genome size in Anthurium evaluated in the context of karyotypes and phenotypes
por: Bliss, Barbara J., et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_6otkbjgvasoj9gu1cc5h3jje3s